Tetanus Infection Drug Development Pipeline Study, H2 2018
Tetanus Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Tetanus Infection pipeline products.
DISEASE OVERVIEW
Tetanus infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.
Different forms of tetanus include%li%general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.
Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include%li%Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma%li%Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.
REPORT DESCRIPTION
The Tetanus Infection pipeline guide presents complete overview of drugs currently being developed for Tetanus Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Tetanus Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Tetanus Infection pipeline candidates is included.
Major companies participating in therapeutic development of Tetanus Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Tetanus Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Tetanus Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Tetanus Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF TETANUS INFECTION PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Tetanus infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.
Different forms of tetanus include%li%general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.
Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include%li%Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma%li%Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.
REPORT DESCRIPTION
The Tetanus Infection pipeline guide presents complete overview of drugs currently being developed for Tetanus Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Tetanus Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Tetanus Infection pipeline candidates is included.
Major companies participating in therapeutic development of Tetanus Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Tetanus Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Tetanus Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Tetanus Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF TETANUS INFECTION PIPELINE REPORT INCLUDES
- Panorama of Tetanus Infection pipeline markets including statistics on therapeutic drugs and companies involved
- Tetanus Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Tetanus Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Tetanus Infection pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Tetanus Infection pipeline therapeutics
- Get clear understanding of the entire Tetanus Infection pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Tetanus Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Tetanus Infection Pipeline include-
Number of Companies with Tetanus Infection projects in pre-clinical Development-
Number of Companies with Tetanus Infection projects in Clinical Development-
Tetanus Infection Pipeline Companies based in Americas
Tetanus Infection Pipeline Companies based in Europe
Tetanus Infection Pipeline Companies based in Asia Pacific
Tetanus Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Tetanus Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Tetanus Infection Pipeline Agents in Clinical Development stage
Tetanus Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Tetanus Infection Pipeline agents
II. INSIGHTS INTO TETANUS INFECTION PIPELINE
1. Disease Overview
Introduction to Tetanus Infection
Symptoms and Causes of Tetanus Infection
Treatment or Prevention Options for Tetanus Infection
Other Details
2. Phase wise Pipeline Compounds
Tetanus Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Tetanus Infection Pipeline- Phase 1 stage Drugs
Tetanus Infection Pipeline- Phase 2 stage Drugs
Tetanus Infection Pipeline- Phase 3 stage Drugs
Tetanus Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Tetanus Infection Pipeline Compounds
4. Tetanus Infection Pipeline by Mechanism of Action
III. TETANUS INFECTION PIPELINE COMPOUND DETAILS
DTaP-IPV-Hib Vaccine
DTaP-Hib vaccine
DTaP Vaccine
DTcP vaccine
BK1310
DTwP-HepB-Hib-IPV vaccine
Diphtheria, Tetanus and Pertussis (Whole Cell) Vaccine
VN-0105
GC3111A
(diphtheria, tetanus, acellular pertussis, hepatitis B recombinent, poliomyelitis, haemophilus influenza type B) vaccine
DPT-H-HiB pentavalent vaccine
LBVD
Adsorbed Acellular Pertussis (tricomponent) vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
(Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b, Polio) vaccine
Adacel+ Tdap booster
(DTP-HepB-Polio-Hib) Pediatric hexavalent vaccine
DTaP Vaccine
vaccine for Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b in Indian children
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. TETANUS INFECTION PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
BIKEN Corporation
Biological E Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Company Ltd
GC Pharma- Korea
GlaxoSmithKline Plc
Indian Immunologicals Ltd
LG Chem Ltd
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi SA
Sanofi Pasteur SA
Serum Institute of India Ltd
Wockhardt Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL TETANUS INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Tetanus Infection Pipeline include-
Number of Companies with Tetanus Infection projects in pre-clinical Development-
Number of Companies with Tetanus Infection projects in Clinical Development-
Tetanus Infection Pipeline Companies based in Americas
Tetanus Infection Pipeline Companies based in Europe
Tetanus Infection Pipeline Companies based in Asia Pacific
Tetanus Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Tetanus Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Tetanus Infection Pipeline Agents in Clinical Development stage
Tetanus Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Tetanus Infection Pipeline agents
II. INSIGHTS INTO TETANUS INFECTION PIPELINE
1. Disease Overview
Introduction to Tetanus Infection
Symptoms and Causes of Tetanus Infection
Treatment or Prevention Options for Tetanus Infection
Other Details
2. Phase wise Pipeline Compounds
Tetanus Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Tetanus Infection Pipeline- Phase 1 stage Drugs
Tetanus Infection Pipeline- Phase 2 stage Drugs
Tetanus Infection Pipeline- Phase 3 stage Drugs
Tetanus Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Tetanus Infection Pipeline Compounds
4. Tetanus Infection Pipeline by Mechanism of Action
III. TETANUS INFECTION PIPELINE COMPOUND DETAILS
DTaP-IPV-Hib Vaccine
DTaP-Hib vaccine
DTaP Vaccine
DTcP vaccine
BK1310
DTwP-HepB-Hib-IPV vaccine
Diphtheria, Tetanus and Pertussis (Whole Cell) Vaccine
VN-0105
GC3111A
(diphtheria, tetanus, acellular pertussis, hepatitis B recombinent, poliomyelitis, haemophilus influenza type B) vaccine
DPT-H-HiB pentavalent vaccine
LBVD
Adsorbed Acellular Pertussis (tricomponent) vaccine
Adsorbed Acellular Pertussis (tricomponent) vaccine
(Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b, Polio) vaccine
Adacel+ Tdap booster
(DTP-HepB-Polio-Hib) Pediatric hexavalent vaccine
DTaP Vaccine
vaccine for Diphtheria, acellular Pertussis, Tetanus and Hemophilus influenza b in Indian children
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. TETANUS INFECTION PIPELINE COMPANY BRIEFS
Beijing Minhai Biotechnology Co Ltd
BIKEN Corporation
Biological E Ltd
Cadila Healthcare Ltd
Daiichi Sankyo Company Ltd
GC Pharma- Korea
GlaxoSmithKline Plc
Indian Immunologicals Ltd
LG Chem Ltd
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi SA
Sanofi Pasteur SA
Serum Institute of India Ltd
Wockhardt Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL TETANUS INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
